Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
Despite remdesivir approval and 2 big buyouts, Gilead CEO Dan O'Day sees pay fall 35% from 2019
For all intents and purposes, 2020 was a busy year for Gilead. The big biotech pulled off two big acquisitions in Forty Seven and Immunomedics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
